Resources
14 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 9/14/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy Town Hall took place on September 1, 2020.
Please find the presentation and recording posted here.
Posted 9/4/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy and Learning Collaborative Orientation Webinar took place on August 25, 2020. Please find the presentation and recording posted here.
Posted 12/30/2019 (updated 3/28/2024)
Pharmacotherapy of Opioid Use Disorder Webinar Presentation and Resources
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 5/5/2020 (updated 3/28/2024)
This was the first session in the telehealth series. There were various speakers and panelists from agencies including JBS International, Global Partnership for Telehealth, H.O.P.E. Telehealth Consortium, HRSA’s Office for the Advancement of Telehealth, and the Telehealth Resource Centers.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.